Effect of the Addition of Cetuximab to Paclitaxel, Cisplatin, and Radiation Therapy for Patients With Esophageal Cancer-Reference-Cited by-同舟云学术

Effect of the Addition of Cetuximab to Paclitaxel, Cisplatin, and Radiation Therapy for Patients With Esophageal Cancer

Published:2017-11-01 Issue:11 Volume:3 Page:1520
ISSN:2374-2437
Container-title:JAMA Oncology
language:en
Short-container-title:JAMA Oncol

Author:

Suntharalingam Mohan¹,Winter Kathryn²,Ilson David³,Dicker Adam P.⁴,Kachnic Lisa⁵,Konski André⁶,Chakravarthy A. Bapsi⁵,Anker Christopher J.⁷,Thakrar Harish⁸,Horiba Naomi⁹,Dubey Ajay¹⁰,Greenberger Joel S.¹¹,Raben Adam¹²,Giguere Jeffrey¹³,Roof Kevin¹⁴,Videtic Gregory¹⁵,Pollock Jondavid¹⁶,Safran Howard¹⁷,Crane Christopher H.¹⁸

Affiliation:

1. University of Maryland Medical System, Baltimore

2. NRG Oncology Statistics and Data Management Center, Philadelphia, Pennsylvania

3. Memorial Sloan-Kettering Cancer Center, New York City, New York

4. Thomas Jefferson University Hospital, Philadelphia, Pennsylvania

5. Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee

6. The Chester County Hospital, West Chester, Pennsylvania

7. Huntsman Cancer Hospital, University of Utah, Salt Lake City

8. MBCCOP, John H. Stroger Jr Hospital of Cook County, Chicago, Illinois

9. University of Maryland Medical System, Baltimore9Food and Drug Administration, Bethesda, Maryland

10. Department of Oncology, USON-Texas, Bedford, Texas

11. Shadyside Hospital, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania

12. Christiana Care Health Services Inc, CCOP, Newark, Delaware

13. Greenville South Carolina, CCOP, Greenville

14. Southeast Cancer Control Consortium Inc, CCOP, Winston Salem, North Carolina

15. Cleveland Clinic, Cleveland, Ohio

16. The Schiffler Cancer Center, Wheeling, West Virginia

17. Brown University Oncology Group, Providence, Rhode Island

18. Memorial Sloan-Kettering Cancer Center, New York City, New York18University of Texas MD Anderson Cancer Center, Houston

Publisher

American Medical Association (AMA)

Subject

Oncology,Cancer Research

Cited by 158 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Patient-reported outcomes (PROs) in NRG Oncology RTOG 0436: a phase III trial evaluating the addition of cetuximab to paclitaxel, cisplatin, and radiation for esophageal cancer treated without surgery;Quality of Life Research;2024-07-27

2. Neoadjuvant radiotherapy combined with fluorouracil-cisplatin plus cetuximab in operable, locally advanced esophageal carcinoma: Results of a phase I-II trial (FFCD-0505/PRODIGE-3);Clinical and Translational Radiation Oncology;2024-07

3. Combinatorial Approaches for Chemotherapies and Targeted Therapies With Radiation: United Efforts to Innovate in Patient Care;International Journal of Radiation Oncology*Biology*Physics;2024-04

4. Radiation therapy, tissue radiosensitization, and potential synergism in the era of novel antibody-drug conjugates;Critical Reviews in Oncology/Hematology;2024-03

5. HMGA1 drives chemoresistance in esophageal squamous cell carcinoma by suppressing ferroptosis;Cell Death & Disease;2024-02-21